Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

被引:2
|
作者
Farooq, Juveriya [1 ,2 ]
Sana, M. M.
Chetana, P. M. [1 ]
Almuqbil, Mansour [3 ]
Bhat, Nagapati Prabhakar [2 ]
Sultana, Rokeya [4 ]
Khaiser, UmaimaFarheen [5 ]
Asdaq, Syed Mohammed Basheeruddin [6 ]
Almalki, Mutlaq Eidhah M. [7 ]
Khormi, Amro Mohammed Sawadi [6 ,7 ]
Albraiki, Salem Ahmad [8 ]
Almadani, Moneer E. [9 ]
机构
[1] Shree Devi Coll Pharm, Dept Pharm Practice, Mangalore 574142, Karnataka, India
[2] Yenepoya Deemed Univ, Dept Pharmacol, Deralakatte 575018, Karnataka, India
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
[4] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharmacognosy, Deralakatte 575018, Karnataka, India
[5] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharm Practice, Deralakatte 575018, Karnataka, India
[6] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh 13713, Saudi Arabia
[7] King Saud Univ Med City, Riyadh, Saudi Arabia
[8] King Abdul Aziz Med City, Dept Pharm, Riyadh, Saudi Arabia
[9] AlMaarefa Univ, Coll Med, Dept Clin Med, Riyadh 13713, Saudi Arabia
关键词
Polypharmacy; Drug-drug interaction; Chronic liver disease; Cirrhosis; Quality of life; BETA-BLOCKERS; CIRRHOSIS; QUESTIONNAIRE;
D O I
10.1016/j.jsps.2023.06.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as ''the administration of many drugs at the same time or the administration of an excessive number of drugs". The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] STUDY FOR DRUG-DRUG INTERACTION IN THE TREATMENT OF CHRONIC DISEASE
    Chae, Jung-Woo
    Beak, Hyun-Moon
    Song, Byung-Jeong
    Lee, Byung-Yo
    Kang, Ho-Il
    Kwon, Kwang-Il
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 50 : E205 - E205
  • [2] Investigation of potential drug-drug interaction in chronic kidney disease patients in nephrology clinic
    Buker, Aysun
    Sosyal, Damla
    Ozmen, Ozge
    Bektay, Muhammed Yunus
    Gursu, Meltem
    Kazancioglu, Rumeyza
    Izzettin, Fikret Vehbi
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1778 - 1778
  • [3] ADVERSE DRUG REACTIONS AND DRUG-DRUG INTERACTION IN CHRONIC KIDNEY DISEASE WITH TUBERCULOSIS
    Datta, Divya
    Prabhu, Ravindra Attur
    Khader, Nisha Abdul
    Nagaraju, Shankar Prasad
    Rao, Indu Ramachandra
    Shenoy, Srinivas Vinayak
    Rangaswamy, Dharshan
    Bhojaraja, Mohan V.
    Thunga, Girish
    Magazine, Rahul
    Shetty, Raghavendra
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I342 - I342
  • [4] Drug-drug interactions in hospitalized patients with chronic obstructive pulmonary disease
    Roblek, Tina
    Trobec, Katja
    Mrhar, Ales
    Lainsc, Mitja
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [5] Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
    Bachmann, Paula
    Frahm, Niklas
    Debus, Jane Louisa
    Mashhadiakbar, Pegah
    Langhorst, Silvan Elias
    Streckenbach, Barbara
    Baldt, Julia
    Heidler, Felicita
    Hecker, Michael
    Zettl, Uwe Klaus
    PHARMACEUTICS, 2022, 14 (03)
  • [6] Prevalence of Potential Drug-Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital
    Santos-Diaz, Gracia
    Maria Perez-Pico, Ana
    Angel Suarez-Santisteban, Miguel
    Garcia-Bernalt, Vanesa
    Mayordomo, Raquel
    Dorado, Pedro
    PHARMACEUTICS, 2020, 12 (08) : 1 - 11
  • [7] Unseen face of polypharmacy in Alzheimer's disease - a focus on drug-drug interactions
    Vrabie, M.
    Marinescu, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S159 - S160
  • [8] Assessment of drug-drug interaction potential among patients with Parkinson's disease
    Montejano, L.
    Foley, K.
    Sander, S.
    Patel, A.
    Shah, H.
    Brunton, S.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S115 - S115
  • [9] Targeting continuity of care and polypharmacy to reduce drug-drug interaction
    Weng, Yi-An
    Deng, Chung-Yeh
    Pu, Christy
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Retrospective Study on Prevalence and Clinical Significance of Possible Drug-Drug Interactions in Prescriptions of Patients with Chronic Liver Disease
    Shamim, Sumbul
    Fareed, Sharjeel
    Ali Masood, Muhammad
    Arshad, Muhammad
    Gul, Huma
    LATIN AMERICAN JOURNAL OF PHARMACY, 2018, 37 (08): : 1587 - 1593